Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX Adjuvant Chemotherapy for Gastroenteric Neuroendocrine Carcinoma
ChiCTR2600128531Phase 4Recruiting
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxaliplatin and capecitabine in neuroendocrine carcinoma (NEC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Disease-Free Survival. Started Jul 2026; status: recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on ChiCTR2600128531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128531.